Lumos Diagnostics Holdings Management
Management criteria checks 2/4
Lumos Diagnostics Holdings' CEO is Doug Ward, appointed in Jun 2022, has a tenure of 2.42 years. total yearly compensation is $773.94K, comprised of 62.7% salary and 37.3% bonuses, including company stock and options. directly owns 0.064% of the company’s shares, worth A$16.62K. The average tenure of the management team and the board of directors is 2.8 years and 3.9 years respectively.
Key information
Doug Ward
Chief executive officer
US$773.9k
Total compensation
| CEO salary percentage | 62.7% |
| CEO tenure | 2.4yrs |
| CEO ownership | 0.06% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.9yrs |
Recent management updates
Recent updates
Lumos Diagnostics Holdings Limited (ASX:LDX) Stock Catapults 35% Though Its Price And Business Still Lag The Industry
Oct 14
There Is A Reason Lumos Diagnostics Holdings Limited's (ASX:LDX) Price Is Undemanding
Aug 29Take Care Before Diving Into The Deep End On Lumos Diagnostics Holdings Limited (ASX:LDX)
Jan 03The Market Lifts Lumos Diagnostics Holdings Limited (ASX:LDX) Shares 387% But It Can Do More
Jul 04Bearish: Analysts Just Cut Their Lumos Diagnostics Holdings Limited (ASX:LDX) Revenue and EPS estimates
Jul 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | US$774k | US$485k | -US$9m |
| Mar 31 2024 | n/a | n/a | -US$9m |
| Dec 31 2023 | n/a | n/a | -US$9m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | US$665k | US$415k | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$25m |
| Dec 31 2022 | n/a | n/a | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | US$472k | US$14k | -US$46m |
Compensation vs Market: Doug's total compensation ($USD773.94K) is above average for companies of similar size in the Australian market ($USD299.27K).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
CEO
Doug Ward
2.4yrs
Tenure
US$773,939
Compensation
Mr. Douglas Ward, also known as Doug, serves as Chief Executive Officer of Lumos Diagnostics Holdings Limited since June 20, 2022 and its Managing Director and Director since July 13, 2023. He was Chief Ex...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 2.4yrs | US$773.94k | 0.064% A$ 16.6k | |
| Chief Financial Officer | 2.8yrs | US$385.34k | no data | |
| Chief Technology Officer | no data | no data | no data | |
| Vice President of Corporate Marketing & Communications | 3.8yrs | no data | no data | |
| Senior Director of Human Resources | 3.9yrs | no data | no data | |
| Senior Vice President of Commercial Operations | 2.8yrs | no data | no data | |
| Company Secretary | no data | no data | no data |
2.8yrs
Average Tenure
Experienced Management: LDX's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, MD & Director | 1.3yrs | US$773.94k | 0.064% A$ 16.6k | |
| Non-Executive Chairman | 5.8yrs | US$182.78k | 0.18% A$ 47.8k | |
| Independent Director | 4yrs | US$65.51k | 0.023% A$ 6.0k | |
| Independent Director | 3.9yrs | US$61.88k | 0.28% A$ 72.5k | |
| Strategic Healthcare Adviser & Member of Medical Advisory Board | 3.2yrs | no data | no data |
3.9yrs
Average Tenure
Experienced Board: LDX's board of directors are considered experienced (3.9 years average tenure).